PPD Development, LP (PPD Clinical Research Unit, Las Vegas)
Las Vegas, Nevada, 89113, United States
NCT Number: NCT06333977
to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Las Vegas, Nevada, 89113, United States
The study will be conducted in 2 parts:
Part 1 (Single Ascending Dose) This part will include 6 sequential dose cohorts (S1-S6).
Part 2 (Multiple Ascending Dose) This part will include 5 sequential dose cohorts (M1-M5). Cohorts M1-M4 will enroll healthy subjects. Cohort M5 will enroll subjects with T2DM.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
For healthy subjects:
Inclusion criteria
Exclusion criteria
For T2DM subjects:
Inclusion criteria
Exclusion criteria
oral dose, once daily
matching placebo
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up to 2 weeks
Time frame: up to 4 weeks
concentration-QTc analysis
Time frame: up to 4 weeks
Time frame: up to 4 weeks
LG Chem
Industry
A First in Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LC542019 in Healthy Subjects and Subjects With T2DM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03133156
Behavior, Body Weight
Boston, Massachusetts, United States
View Trial DetailsNCT04262128
Behavior, Cardiovascular Diseases
Aurora, Colorado, United States
View Trial DetailsNCT06586775
Diabetes Mellitus, Diabetes Mellitus, Type 2
Rohtak, Haryana, India
View Trial DetailsNCT04616027
Diabetes Mellitus, Diabetes Mellitus, Type 2
Miami, Florida, United States
View Trial Details